SCHEMBL20916459

SCHEMBL20916459

CC(C)Cc1c(C(=O)N2CCC2)c(Cl)cc2c1ccn2C(=O)OCc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.37
HSD11B1 P28845 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
TMEM97 Q5BJF2 4/20 0.35
SIGMAR1 Q99720 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CTSK P43235 3/20 0.34
CTSL P07711 2/20 0.34
CTSS P25774 2/20 0.34
SPR P35270 1/20 0.34
ABL1 P00519 1/20 0.34
RIN1 Q13671 1/20 0.34
S1PR3 Q99500 1/20 0.34
ACE2 Q9BYF1 2/20 0.34
CYP2C19 P33261 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20916667 0.86 HPGD (0.40) DPP4HSD11B1MEN1KMT2ANPSR1
SCHEMBL20916513 0.80 SMN1; SMN2 (0.39) HSD11B1MEN1KMT2ANPSR1TMEM97
SCHEMBL20916543 0.78 JAK2 (0.37) TMEM97SIGMAR1SMN1; SMN2NPC1RAB9A
SCHEMBL20916477 0.74 ALDH1A1 (0.39) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL20916576 0.73 MAPT (0.46) NPSR1SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL20916603 0.70 PIK3CA (0.33) SPR
SCHEMBL20916676 0.69 AKT1 (0.37)
SCHEMBL20916590 0.69 BCL6 (0.31)
SCHEMBL20916643 0.69 GAA (0.42) MEN1KMT2ASMN1; SMN2NPC1SPR
SCHEMBL20916635 0.68 MAPT (0.32) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793551-B2 Benzimidazole-indole inhibitors of Mnk1 and Mnk2 Effector Therapeutics Inc. (US) 2020-10-06 US disclosed
EP-3697777-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 eFFECTOR Therapeutics, Inc. (US) 2020-08-26 EP disclosed
US-20190119256-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (JP) 2019-04-25 US disclosed
WO-2019079369-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 EFFECTOR THERAPEUTICS, INC. (US) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119256-A1 BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 NEK5, MINK1, NIM1K DPP4 3952/4885HSD11B1 3250/4885MEN1 471/4885
US-10793551-B2 Benzimidazole-indole inhibitors of Mnk1 and Mnk2 NEK5, MINK1, NIM1K DPP4 3952/4885HSD11B1 3250/4885MEN1 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.